Mundipharma
Also known as: CHG Pontoise / SAMU 95 | Department Head, Clinical Trial Operations, Clinical Development, Mundipharma K.K. | MUNDIPHARMA | Mundipharma AB | Mundipharma, China | Mundipharma China Ltd. | Mundipharma (China) Pharmaceutical Co. Ltd | Mundipharma CVA | Mundipharma Distribution GmBH (Philippine Branch) | Mundipharma-EDO GmbH | Mundipharma Finland | Mundipharma (Hong Kong) Ltd | Mundipharma K.K. | Mundipharma Korea Ltd | Mundipharma Manufacturing Pte Ltd. | Mundipharma Medical Company | Mundipharma Oy | Mundipharma Pharmaceuticals B.V. | Mundipharma Pharmaceuticals Sdn. Bhd. | Mundipharma Pharmaceuticals S.L. | Mundipharma Pharmaceuticals srl | Mundipharma Pte Ltd. | Mundipharma Research GmbH & Co KG | Mundipharma Research Limited | Mundipharma Research Ltd | Mundipharma SAS | Norpharma A/S | Norpharma A/S, Slotsmarken 15, DK-2970 Hoersholm, Denmark | Taiwan Mundipharma Pharmaceuticals Ltd.
Highest phase reached
Phase 4
Timeline
1960s
- Jan 1, 1967
Mundipharma— Founded
2000s
- Sep 2, 2008
Clinical Designs Limited— Acquired
2010s
- Oct 10, 2018
Cinfa Biotech— Acquired
2020s
- Mar 22, 2023
rezafungin— Marketing Organization
Drugs by trial phase (55 distinct, 134 trials)
Phase 4 (16 own, 0 via acquisition)
Phase 3 (16 own, 0 via acquisition)
Phase 2 (18 own, 0 via acquisition)
Phase 1 (3 own, 2 via acquisition)
Indications
Studied for
- Acne Vulgaris
- Acute Pain
- Aggression
- Arthralgia
- Arthritis
- Arthritis, Rheumatoid
- Asthma
- Back Pain
- Cancer Pain
- Chronic Pain
- Constipation
- Cystitis
- Cystitis, Interstitial
- Diabetic Neuropathies
- Disease
- Disease Progression
- Emergencies
- Endometrial Neoplasms
- Giant Cell Arteritis
- Glioblastoma
- Gliosarcoma
- Herpes Zoster
- Hodgkin Disease
- Hyperplasia
- Inflammation
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Prolymphocytic
- Leukemia, Prolymphocytic, T-Cell
- Low Back Pain
- Lower Urinary Tract Symptoms
- Lung Diseases
- Lung Diseases, Obstructive
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Melanoma
- Meningeal Carcinomatosis
- Mucositis
- Multiple Myeloma
- Myalgia
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Osteoarthritis
- Ovarian Neoplasms
- Pain
- Parkinson Disease
- Peripheral Nervous System Diseases
- Polymyalgia Rheumatica
- Polyneuropathies
- Postoperative Pain
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Hyperplasia
- Pulmonary Disease, Chronic Obstructive
- Sarcoma
- Small Cell Lung Carcinoma
- Spinal Cord Diseases
- Spinal Diseases
- Syndrome
- Tissue Adhesions
- Triple Negative Breast Neoplasms
- Wounds and Injuries
Marketed drugs (1)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT06794554Lead sponsorPhase 2Mar 1, 2025
- NCT05835479Study directorPhase 2Oct 31, 2023
- NCT05835479Lead sponsorPhase 2Oct 31, 2023
- NCT05534529Lead sponsorPhase 1Feb 1, 2023
- NCT05432375Study directorEarly Phase 1Jul 1, 2022
- NCT05432375Lead sponsorEarly Phase 1Jul 1, 2022
- NCT04271839Lead sponsorPhase 4Apr 30, 2020
- NCT04271839Reponsible party - principal investigatorPhase 4Apr 30, 2020
- NCT04124510Lead sponsorPhase 3Dec 31, 2019
- NCT03975010Lead sponsorPhase 1May 13, 2019
- NCT03967327Lead sponsorPhase 3Apr 22, 2019
- NCT03768466Lead sponsorPhase 4Nov 21, 2018
- NCT04279938CollaboratorPhase 1Sep 30, 2018
- NCT03687125Lead sponsorPhase 1/Phase 2Sep 19, 2018
- NCT03452930CollaboratorPhase 1Aug 13, 2018
Details
- Founded
- Limburg, DE Jan 1, 1967
- Last known activity
- Mar 1, 2025